Amicus Therap Us Company Profile

What is the competitive landscape for AMICUS THERAP US

AMICUS THERAP US has two approved drugs.

There are seventy-three US patents protecting AMICUS THERAP US drugs.

There are four hundred and twenty-nine patent family members on AMICUS THERAP US drugs in forty-five countries and thirty-three supplementary protection certificates in eighteen countries.

Summary for Amicus Therap Us

International Patents:	429
US Patents:	73
Tradenames:	2
Ingredients:	2
NDAs:	2

Drugs and US Patents for Amicus Therap Us

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	11,813,255
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	11,903,938			Y
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	11,612,593			Y

International Patents for Amicus Therap Us Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	4541418
World Intellectual Property Organization (WIPO)	2008134628
South Korea	102631805

Supplementary Protection Certificates for Amicus Therap Us Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3201320	CA 2024 00012	Denmark		PRODUCT NAME: CIPAGLUCOSIDASE ALFA; REG. NO/DATE: EU/1/22/1714 20230324
2787345	634	Finland
2787345	201640042	Slovenia		PRODUCT NAME: MIGALASTAT OR ITS SALT, INCLUDING HYDROCHLORIDE SALT; NATIONAL AUTHORISATION NUMBER: EU/1/15/1082/001; DATE OF NATIONAL AUTHORISATION: 20160526; AUTHORITY FOR NATIONAL AUTHORISATION: EU

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Amici Pharma
• Amicus Therap Us

Pharmaceutical Competitive Landscape Analysis: Amicus Therapeutics – Market Position, Strengths & Strategic Insights

Last updated: January 25, 2026

Executive Summary

Amicus Therapeutics (AMTX), a biotechnology firm specializing in rare and orphan diseases, commands a notable position within the biopharmaceutical landscape. With a diversified portfolio primarily in neuromuscular and neurodegenerative disorders, Amicus leverages innovative enzyme replacement therapies (ERTs) and pharmacological chaperones to differentiate itself. This report provides an in-depth analysis of Amicus's market position, core strengths, competitive landscape, and strategic outlook, offering critical insights to stakeholders evaluating industry dynamics and investment opportunities.

---

Current Market Position of Amicus Therapeutics

Company Overview

Aspect	Details
Head Office	Cranbury, New Jersey, USA
Founded	2002
Revenue (2022)	~$172 million
R&D Investment (2022)	~$80 million (approx. 47% of revenue)
Key Programs	Galafold (migalastat), AT-GAA (Pompe disease), AMF-421
Market Cap (March 2023)	~$757 million
Focus Areas	Rare genetic diseases, enzyme replacement, chaperone therapies

Market Segmentation & Revenue Breakdown

Therapeutic Area	Revenue % (2022)	Key Products / Developmental Assets
Fabry Disease (Glaa-/-)	82%	Galafold (migalastat) – Approved global ERT and pharmacological chaperone
Pompe Disease (GAA deficiency)	10%	AT-GAA – Investigational enzyme therapy
Other Rare Diseases	8%	Pipeline pipeline (e.g., AMF-421 for other indications)

Note: Galafold remains Amicus’s cash cow, with global sales surpassing $237 million in 2022, though facing competitive and pricing pressures.

Global Footprint & Market Share

Region	Estimated Market Share	Key Competitors
North America	~55%	Sanofi Genzyme, Amneal, Chiesi
Europe	~30%	Recordati, Sanofi, Takeda
Rest of World	~15%	Local generic and biotech entrants

Amicus maintains a dominant position in the Fabry disease market but faces competition from established players like Sanofi Genzyme and emerging biotech firms.

---

Strengths of Amicus Therapeutics

Innovative Portfolio Focused on Rare Diseases

• Market Niche: Specializes exclusively in rare and ultra-rare genetic disorders.
• Product Differentiation: Combines pharmacological chaperone technology (Galafold) with enzyme replacement therapies.

Proprietary Technologies & Pipeline Assets

• Migalastat (Galafold): First oral pharmacological chaperone approved for Fabry disease.
• Next-generation ERTs: Advancing AT-GAA and other biologics with improved tissue targeting and immune profile.
• Pipeline Expansion: Multiple IND-ready candidates for lysosomal storage disorders, neuromuscular diseases, and neurodegeneration.

Strategic Collaborations & Licensing

• Partnerships with pharmaceutical giants like Sanofi for commercial rights.
• Academic Collaborations: Integration of cutting-edge research in molecular chaperoning and enzyme delivery.

Market Acceptance & Regulatory Milestones

• Regulatory Approvals: Galafold approved in over 40 countries, including FDA (2018) and EMA (2019).
• Orphan Drug Designation: Facilitates market exclusivity and incentives.

Financial Strategic Positioning

• Focused R&D Spend: High R&D-to-sales ratio sustains innovation pipeline.
• Cost-Effective Operations: Lean operational model relative to larger rivals.

---

Strategic Challenges & Threats

Challenge / Threat	Details
Limited Product Portfolio	Heavy reliance on Galafold sales; pipeline needs rapid expansion.
Pricing & Reimbursement Risks	Price pressures in key markets threaten revenue growth.
Market Competition in Rare Diseases	Larger players investing in similar therapies (e.g., Sanofi, Takeda).
Manufacturing Complexity & Cost	Biologic production requires high capital and logistical precision.
Regulatory and Reimbursement Hurdles	Variable approval timelines and reimbursement policies across regions.

---

Competitive Landscape

Major Competitors & Benchmarking

Company	Core Focus	Market Cap (2023)	Key Drugs/Assets	Competitive Advantage
Sanofi Genzyme	Multiple rare disease therapies	~$125B	Fabry (Replagal), Gaucher, others	Large global footprint, diversified pipeline
Amneal Pharmaceuticals	Generic biologics & biosimilars	~$1.4B	Developing Fabry & other rare disease candidates	Cost leadership, manufacturing scale
Takeda Pharmaceutical	Rare diseases, neurodegeneration	~$65B	Velcade, Natpara, others	Extensive R&D, global reach
Regenxbio / Roche	Gene therapies	Varies, private	Gene therapy candidates in multiple areas	Innovative gene delivery platforms
Tiny biotech startups	Niche rare disease treatments	Niche	Various, early-stage assets	Fast innovation cycles, niche focus

Market Positioning Summary

Parameter	Amicus	Competitors
Patent Portfolio	Focused on enzyme chaperoning, limited patent breadth	Broader, includes biologics, gene therapy patents
Revenue Streams	Primarily drug sales, licensing	Diversified: from biologics, gene, and cell therapy
Innovation Focus	Rare diseases, enzyme stabilization	Broad spectrum: biologics, gene editing, cell therapy

Key Strategic Insights

• Niche Leadership: Amicus’s specialization confers a competitive advantage, yet requires rapid pipeline advancements to sustain growth.
• Partnership Leverage: Collaboration with large pharma enhances market reach but exposes dependency risks.
• Pipeline Development: Critical focus on expanding indications beyond Fabry and Pompe diseases.
• Global Expansion: Regulatory approvals in key markets (US, EU, Japan) are central to growth.

---

Strategic Outlook & Recommendations

Emerging Opportunities

• Pipeline Expansion: Accelerate clinical development for AT-GAA, AMF-421, and other candidates.
• Gene Therapy Integration: Explore partnerships or in-house development for gene therapy platforms.
• Market Expansion: Leverage recent approvals for introducing Galafold into emerging markets with high unmet need.
• Manufacturing Optimization: Invest in scalable biologics manufacturing to reduce costs and meet global demand.

Risks to Monitor

• Pricing Pressures: Potential reimbursement restrictions in dominant markets.
• Regulatory Delays: Approval uncertainties particularly for pipeline assets.
• Competitive Innovations: Advances in gene therapy and CRISPR platforms by competitors could diminish niche advantages.

Strategic Recommendations

Action Item	Rationale
Diversify pipeline assets for multiple rare diseases	Reduce over-reliance on Fabry/glycosylation disorders
Invest in next-generation delivery technologies	Enhance tissue targeting and reduce immune responses
Strengthen global market access and reimbursement strategies	Maximize revenue potential in emerging economies
Explore strategic M&A opportunities	Acquire complementary technologies or assets with shorter R&D cycles

---

Comparison Table: Amicus vs. Key Competitors

Attribute	Amicus	Sanofi Genzyme	Takeda	Others
Market Cap (2023)	~$757 million	~$125 billion	~$65 billion	Varies
Focus	Rare genetic disorders	Broad rare diseases	Neurodegeneration, rare diseases	Narrow, niche biotech firms
Key Assets	Galafold, AT-GAA	Replagal, Fabrazyme	Velcade, Natpara	Pipeline assets
R&D Intensity (%)	~47% of revenue	~15-20% of revenue	~13-17%	Varies
Pipeline Focus	Enzyme stabilization, chaperones	Enzymes, gene therapy	Gene therapy, biologics	Gene editing, biologics

---

Conclusion

Amicus Therapeutics occupies a distinctive niche within the rare disease segment, leveraging innovative enzyme stabilization technologies and a strategic focus on ultra-rare disorders. While current market dominance in Fabry disease offers revenue stability, future growth depends on successful pipeline expansion, technological innovation, and effective market access strategies. The competitive landscape is characterized by large, diversified pharmaceutical companies with broader portfolios, but Amicus’s specialized positioning and proprietary technologies provide unique leverage if bolstered by accelerated pipeline development and strategic collaborations.

---

Key Takeaways

• Strengths: Proprietary enzyme chaperone technology, strong pipeline, regulatory approvals for Galafold.
• Challenges: Heavy dependence on a single marketed product, limited pipeline breadth, reimbursement risks.
• Opportunities: Pipeline expansion into new rare disorders, gene therapy integration, global market penetration.
• Threats: Competitive innovations, pricing pressures, regulatory uncertainties.
• Strategic Focus: Diversify assets, foster strategic partnerships, invest in next-generation delivery and manufacturing capabilities.

---

Frequently Asked Questions (FAQs)

1. What is Amicus Therapeutics’s core competitive advantage?
   Its specialized focus on rare and ultra-rare genetic diseases, combined with the development of pharmacological chaperones like Galafold—the only oral therapy approved for Fabry disease—constitutes its core advantage.

2. How does Amicus compare to larger competitors like Sanofi in the rare disease space?
   While Sanofi benefits from a broader portfolio, extensive R&D resources, and global reach, Amicus’s niche expertise and proprietary technologies enable it to carve out a leadership position in specific ultra-rare disorder markets.

3. What is the outlook for Amicus’s pipeline development?
   Accelerated clinical trial timelines and successful regulatory approvals for pipeline candidates such as AT-GAA will be pivotal. The company’s pipeline focus on enzyme stabilization and gene therapy adjacencies offers promising growth avenues but requires ongoing R&D investments.

4. What are the main risks facing Amicus’s growth strategy?
   Major risks include patent challenges, regulatory delays, pricing and reimbursement pressures, and increasing competition from gene therapy and other innovative treatment modalities.

5. What strategic moves should Amicus prioritize?
   Expanding pipeline breadth, investing in next-generation delivery platforms, forging strategic partnerships, and increasing global market access are critical to sustain growth and mitigate competitive threats.

---

References

[1] Amicus Therapeutics Annual Report 2022.
[2] FDA and EMA approvals data for Galafold.
[3] Market data from Evaluate Pharma, March 2023.
[4] Industry reports on rare disease therapeutics.
[5] Competitor financial disclosures and press releases.

---

[End of Report]